Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
4-HO-DiPT is not habit-forming, and the desire to use it can actually decrease with regular consumption. Like most tryptamine psychedelics, it is considered self-regulating.
No physical dependence has been reported. As a tryptamine psychedelic, it does not produce physical withdrawal symptoms.
The exact toxic dose is unknown. The toxicity and long-term health effects of recreational use have not been studied in any scientific context due to its status as a research chemical with very limited history of human usage.
Delusions are listed among possible cognitive effects. As with other psychedelics, adverse psychological reactions may become more likely at higher doses, though specific psychosis risk data for this substance has not been established.
Seizure risk has not been specifically studied for this substance.
4-HO-DiPT was first described in the scientific literature in 1977, with its synthesis published by chemist David B. Repke. Two decades later, Alexander Shulgin investigated the substance's effects in humans and characterized it in his 1997 book TiHKAL ("Tryptamines I Have Known and Loved").…
Listed in the government decree on psychoactive substances prohibited from the consumer market, restricting sale and distribution to consumers.
Controlled under the Pharmaceutical Affairs Law as a Designated Substance. Both possession and sale are prohibited under this classification.
Not listed under Buchstabe A, B, C, or D of the Swiss controlled substances regulations. Generally considered legal, though status should be verified with current regulations.
Not scheduled at the federal level. However, it may be considered an analogue of psilocin (4-HO-DMT) or 5-MeO-DiPT, potentially subjecting purchase, sale, or possession to prosecution under the Federal Analogue Act when intended for human consumption. The DEA proposed scheduling in January 2022 but withdrew the proposal in July 2022 following public response.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production, import with intent to distribute, administration to others, and trading are criminally punishable. Possession is prohibited but not subject to criminal penalty. Use is permitted only for industrial and scientific purposes.
Classified as a 'health hazard' under the Lagen om förbud mot vissa hälsofarliga varor (Act on the Prohibition of Certain Goods Dangerous to Health) as of March 1, 2005, per regulation SFS 2005:26. Both possession and sale are prohibited.
Controlled as a Class A substance under the Misuse of Drugs Act 1971 due to the tryptamine catch-all clause, which covers substituted tryptamines regardless of whether they are individually named in the schedules.
Listed as '4-Hydroxy-N,N-diisopropyltryptamine' as a Schedule I controlled substance under Florida state law, making it illegal to buy, sell, or possess within the state.
12 sources cited
